AI Article Synopsis

  • Anxioselective agents target the alpha(2)beta(x)gamma(2) subtype of the GABA(A)/benzodiazepine receptor complex, acting as agonists to reduce anxiety without sedation.
  • Subtle structural differences among benzodiazepine receptor subtypes make it easier to develop selective agents that show efficacy specifically at the alpha(2) subtype.
  • A screening of indol-3-ylglyoxylamides identified compounds 1c and 2b, which demonstrate potential as non-sedative anxiolytic agents with selective effects on anxiety.

Article Abstract

Anxioselective agents may be identified among compounds binding selectively to the alpha(2)beta(x)gamma(2) subtype of the gamma-aminobutyric acid-A (GABA(A))/central benzodiazepine receptor (BzR) complex and behaving as agonists or among compounds binding with comparable potency to various BzR subtypes but eliciting agonism only at the alpha(2)beta(x)gamma(2) receptor. Because of subtle steric differences among BzR subtypes, the latter approach has proved much more successful. A biological screening within the class of indol-3-ylglyoxylamides 1-3 allowed us to identify compounds 1c and 2b as potential anxiolytic/nonsedative agents showing alpha(2) selective efficacy in vitro and anxioselective effects in vivo. According to molecular modeling studies, and consistently with SARs accumulated in the past decade, 5-NO(2)- and 5-H-indole derivatives would preferentially bind to BzR by placing the indole ring in the L(Di) and the L(2) receptor binding sites, respectively.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm9001154DOI Listing

Publication Analysis

Top Keywords

anxiolytic/nonsedative agents
8
gamma-aminobutyric acid-a
8
benzodiazepine receptor
8
compounds binding
8
bzr subtypes
8
identification anxiolytic/nonsedative
4
agents indol-3-ylglyoxylamides
4
indol-3-ylglyoxylamides acting
4
acting functionally
4
functionally selective
4

Similar Publications

The classical benzodiazepines (Bz) constitute a well-known class of therapeutics displaying hypnotic, anxiolytic and anticonvulsant effects acting upon a specific binding site (BzR) belonging to the GABAA receptor complex. Their usefulness, however, is limited by a broad range of side effects; consequently the fact that the action of GABA with the receptor complex could be allosterically modulated by a wide variety of chemical entities, made the Bz binding site, from late eighties to nowdays, the target of extensive research programmes directed to the identification of new ligands displaying varying degrees of affinity- and efficacy-selectivity for the different GABAA/BzR-subtypes. The principal aim has been to discover ideal sedative-hypnotic agents (selective 1 agonists), anxiolytic agents (selective 2/ 3 agonists), or cognitive enhancers (selective 5 inverse agonists).

View Article and Find Full Text PDF
Article Synopsis
  • Anxioselective agents target the alpha(2)beta(x)gamma(2) subtype of the GABA(A)/benzodiazepine receptor complex, acting as agonists to reduce anxiety without sedation.
  • Subtle structural differences among benzodiazepine receptor subtypes make it easier to develop selective agents that show efficacy specifically at the alpha(2) subtype.
  • A screening of indol-3-ylglyoxylamides identified compounds 1c and 2b, which demonstrate potential as non-sedative anxiolytic agents with selective effects on anxiety.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!